BRPI0414772A - derivado de quinazolina, composto, processo para a preparação de um derivado de quinazolina, composição farmacêutica, uso de um derivado de quinazolina, e, método para produzir um efeito anti-proliferativo em um animal de sangue quente - Google Patents
derivado de quinazolina, composto, processo para a preparação de um derivado de quinazolina, composição farmacêutica, uso de um derivado de quinazolina, e, método para produzir um efeito anti-proliferativo em um animal de sangue quenteInfo
- Publication number
- BRPI0414772A BRPI0414772A BRPI0414772-3A BRPI0414772A BRPI0414772A BR PI0414772 A BRPI0414772 A BR PI0414772A BR PI0414772 A BRPI0414772 A BR PI0414772A BR PI0414772 A BRPI0414772 A BR PI0414772A
- Authority
- BR
- Brazil
- Prior art keywords
- quinazoline derivative
- compound
- producing
- pharmaceutical composition
- warm
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
"DERIVADO DE QUINAZOLINA, COMPOSTO, PROCESSO PARA A PREPARAçãO DE UM DERIVADO DE QUINAZOLINA, COMPOSIçãO FARMACêUTICA, USO DE UM DERIVADO DE QUINAZOLINA, E, MéTODO PARA PRODUZIR UM EFEITO ANTI-PROLIFERATIVO EM UM ANIMAL DE SANGUE QUENTE". A invenção refere-se a derivados de quinazolina de Fórmula sendo que cada um de R¬ 1a¬ , R¬ 1b¬, R¬ 2¬, R¬ 3¬ e a tem quaisquer dos significados definidos na descrição; processos para sua preparação, composições farmacêuticas contendo os mesmos, e seu uso na fabricação de um medicamento para uso como um agente antiproliferativo na prevenção ou no tratamento de tumores que são sensíveis à inibição de tirosinas quinases de receptor de erbB.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0322409.4A GB0322409D0 (en) | 2003-09-25 | 2003-09-25 | Quinazoline derivatives |
PCT/GB2004/004137 WO2005030765A1 (en) | 2003-09-25 | 2004-09-22 | Quinazoline derivatives as antiproliferative agents |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0414772A true BRPI0414772A (pt) | 2006-11-21 |
Family
ID=29286773
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0414772-3A BRPI0414772A (pt) | 2003-09-25 | 2004-09-22 | derivado de quinazolina, composto, processo para a preparação de um derivado de quinazolina, composição farmacêutica, uso de um derivado de quinazolina, e, método para produzir um efeito anti-proliferativo em um animal de sangue quente |
Country Status (14)
Country | Link |
---|---|
US (2) | US7838530B2 (pt) |
EP (1) | EP1668006A1 (pt) |
JP (1) | JP2007506725A (pt) |
KR (1) | KR20060095767A (pt) |
CN (2) | CN100577658C (pt) |
AU (1) | AU2004276067A1 (pt) |
BR (1) | BRPI0414772A (pt) |
CA (1) | CA2540019A1 (pt) |
GB (1) | GB0322409D0 (pt) |
IL (1) | IL174533A0 (pt) |
MX (1) | MXPA06003422A (pt) |
NO (1) | NO20061746L (pt) |
WO (1) | WO2005030765A1 (pt) |
ZA (2) | ZA200602434B (pt) |
Families Citing this family (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0126433D0 (en) * | 2001-11-03 | 2002-01-02 | Astrazeneca Ab | Compounds |
CN100343238C (zh) * | 2001-11-03 | 2007-10-17 | 阿斯特拉曾尼卡有限公司 | 用作抗肿瘤药物的喹唑啉衍生物 |
US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
GB0309009D0 (en) * | 2003-04-22 | 2003-05-28 | Astrazeneca Ab | Quinazoline derivatives |
GB0309850D0 (en) * | 2003-04-30 | 2003-06-04 | Astrazeneca Ab | Quinazoline derivatives |
JP4795952B2 (ja) * | 2003-09-16 | 2011-10-19 | アストラゼネカ アクチボラグ | チロシンキナーゼ阻害剤としてのキナゾリン誘導体 |
WO2005026157A1 (en) * | 2003-09-16 | 2005-03-24 | Astrazeneca Ab | Quinazoline derivatives |
US20080234263A1 (en) * | 2003-09-16 | 2008-09-25 | Laurent Francois Andre Hennequin | Quinazoline Derivatives |
GB0321648D0 (en) * | 2003-09-16 | 2003-10-15 | Astrazeneca Ab | Quinazoline derivatives |
CA2539022A1 (en) * | 2003-09-16 | 2005-03-24 | Astrazeneca Ab | Quinazoline derivatives as tyrosine kinase inhibitors |
GB0326459D0 (en) * | 2003-11-13 | 2003-12-17 | Astrazeneca Ab | Quinazoline derivatives |
US7632840B2 (en) * | 2004-02-03 | 2009-12-15 | Astrazeneca Ab | Quinazoline compounds for the treatment of hyperproliferative disorders |
WO2005118572A1 (en) * | 2004-06-04 | 2005-12-15 | Astrazeneca Ab | Quinazoline derivatives as erbb receptor tyrosine kinases |
US9512125B2 (en) | 2004-11-19 | 2016-12-06 | The Regents Of The University Of California | Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents |
DE602005026865D1 (de) * | 2004-12-14 | 2011-04-21 | Astrazeneca Ab | Pyrazolopyrimidinverbindungen als antitumormittel |
GB0504474D0 (en) * | 2005-03-04 | 2005-04-13 | Astrazeneca Ab | Chemical compounds |
GB0508717D0 (en) * | 2005-04-29 | 2005-06-08 | Astrazeneca Ab | Chemical compounds |
GB0508715D0 (en) * | 2005-04-29 | 2005-06-08 | Astrazeneca Ab | Chemical compounds |
JP2008545008A (ja) * | 2005-06-30 | 2008-12-11 | プロシディオン・リミテッド | Gpcrアゴニスト |
WO2007023073A2 (de) * | 2005-08-22 | 2007-03-01 | Boehringer Ingelheim International Gmbh | Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
US7820683B2 (en) * | 2005-09-20 | 2010-10-26 | Astrazeneca Ab | 4-(1H-indazol-5-yl-amino)-quinazoline compounds as erbB receptor tyrosine kinase inhibitors for the treatment of cancer |
EP1940825A1 (en) * | 2005-09-20 | 2008-07-09 | Astra Zeneca AB | Quinazoline derivatives as anticancer agents |
EP1960371B1 (en) * | 2005-12-02 | 2009-09-16 | AstraZeneca AB | Quinazoleine derivatives used as inhibitors of erbb tyrosine kinase |
US20100222344A1 (en) * | 2005-12-02 | 2010-09-02 | Astrazeneca Ab | 4-anilino-substituted quinazoline derivatives as tyrosine kinase inhibitors |
CA2647391C (en) | 2006-04-04 | 2015-12-29 | The Regents Of The University Of California | Kinase antagonists |
EP1921070A1 (de) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung |
WO2008095847A1 (de) | 2007-02-06 | 2008-08-14 | Boehringer Ingelheim International Gmbh | Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
TWI377944B (en) * | 2007-06-05 | 2012-12-01 | Hanmi Holdings Co Ltd | Novel amide derivative for inhibiting the growth of cancer cells |
EP2190287B1 (en) * | 2007-09-10 | 2014-10-29 | Curis, Inc. | Tartrate salts or complexes of quinazoline based egfr inhibitors containing a zinc binding moiety |
US20110160232A1 (en) | 2007-10-04 | 2011-06-30 | Pingda Ren | Certain chemical entities and therapeutic uses thereof |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
KR101897881B1 (ko) | 2008-01-04 | 2018-09-12 | 인텔리카인, 엘엘씨 | 특정 화학 물질, 조성물 및 방법 |
AU2009211523B2 (en) | 2008-02-07 | 2014-03-13 | Boehringer Ingelheim International Gmbh | Spirocyclic heterocycles, medicaments containing said compounds, use thereof and method for their production |
WO2009114874A2 (en) | 2008-03-14 | 2009-09-17 | Intellikine, Inc. | Benzothiazole kinase inhibitors and methods of use |
US8637542B2 (en) | 2008-03-14 | 2014-01-28 | Intellikine, Inc. | Kinase inhibitors and methods of use |
JP5504158B2 (ja) * | 2008-06-25 | 2014-05-28 | 学校法人慶應義塾 | 医薬組成物 |
CN102124009B (zh) | 2008-07-08 | 2014-07-23 | 因特利凯公司 | 激酶抑制剂及其使用方法 |
WO2010006072A2 (en) | 2008-07-08 | 2010-01-14 | The Regents Of The University Of California | Mtor modulators and uses thereof |
EP2149565A1 (de) * | 2008-07-24 | 2010-02-03 | Bayer Schering Pharma AG | Sulfonsubstituierte Chinazolinderivate als Immunmodulatoren zur Behandlung von enzündlichen und allergischen Erkrankungen |
CA2733153C (en) | 2008-08-08 | 2016-11-08 | Boehringer Ingelheim International Gmbh | Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them |
US8703778B2 (en) | 2008-09-26 | 2014-04-22 | Intellikine Llc | Heterocyclic kinase inhibitors |
WO2010045542A2 (en) | 2008-10-16 | 2010-04-22 | The Regents Of The University Of California | Fused ring heteroaryl kinase inhibitors |
US8476431B2 (en) | 2008-11-03 | 2013-07-02 | Itellikine LLC | Benzoxazole kinase inhibitors and methods of use |
JP5789252B2 (ja) | 2009-05-07 | 2015-10-07 | インテリカイン, エルエルシー | 複素環式化合物およびその使用 |
WO2011047384A2 (en) | 2009-10-16 | 2011-04-21 | The Regents Of The University Of California | Methods of inhibiting ire1 |
EP2571357B1 (en) | 2010-05-21 | 2016-07-06 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
KR101217526B1 (ko) * | 2010-06-11 | 2013-01-02 | 한미사이언스 주식회사 | 아마이드 유도체 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물 |
WO2012064973A2 (en) | 2010-11-10 | 2012-05-18 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8809349B2 (en) | 2011-01-10 | 2014-08-19 | Infinity Pharmaceuticals, Inc. | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
US9295673B2 (en) | 2011-02-23 | 2016-03-29 | Intellikine Llc | Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof |
KR101317809B1 (ko) | 2011-06-07 | 2013-10-16 | 한미약품 주식회사 | 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물 |
CN103930422A (zh) | 2011-07-19 | 2014-07-16 | 无限药品股份有限公司 | 杂环化合物及其用途 |
JP6027611B2 (ja) | 2011-07-19 | 2016-11-16 | インフィニティー ファーマシューティカルズ, インコーポレイテッド | 複素環式化合物及びその使用 |
AU2012302197B2 (en) | 2011-08-29 | 2016-01-07 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
MX370814B (es) | 2011-09-02 | 2020-01-08 | Univ California | Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas. |
KR101272613B1 (ko) | 2011-10-05 | 2013-06-10 | 한미사이언스 주식회사 | 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온 염산염의 제조 방법 및 이에 사용되는 중간체 |
TWI577671B (zh) | 2011-11-14 | 2017-04-11 | Sunshine Lake Pharma Co Ltd | Aminoquinazoline derivatives and salts thereof and methods of use thereof |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
AU2013323426A1 (en) | 2012-09-26 | 2015-04-23 | The Regents Of The University Of California | Modulation of ire1 |
KR20140096571A (ko) * | 2013-01-28 | 2014-08-06 | 한미약품 주식회사 | 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법 |
US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
JP6466924B2 (ja) | 2013-10-04 | 2019-02-06 | インフィニティー ファーマシューティカルズ, インコーポレイテッド | 複素環式化合物及びその使用 |
AP2016009407A0 (en) | 2014-03-17 | 2016-08-31 | Pfizer | Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders |
DK3119397T3 (da) | 2014-03-19 | 2022-03-28 | Infinity Pharmaceuticals Inc | Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser |
WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CN105130913A (zh) * | 2015-08-25 | 2015-12-09 | 佛山市赛维斯医药科技有限公司 | 一类多取代的苯并喹唑啉类酪氨酸激酶抑制剂及用途 |
CN105017164A (zh) * | 2015-08-25 | 2015-11-04 | 佛山市赛维斯医药科技有限公司 | 含新型苯并喹唑啉和邻位氯结构的酪氨酸激酶抑制剂及用途 |
KR20180058741A (ko) | 2015-09-14 | 2018-06-01 | 인피니티 파마슈티칼스, 인코포레이티드 | 이소퀴놀리논의 고체형, 그의 제조 방법, 이를 포함하는 조성물 및 이를 사용하는 방법 |
WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
CN106045980B (zh) * | 2016-06-03 | 2017-11-03 | 江苏开放大学 | 一种喹唑啉衍生物及其制备方法 |
US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CA3028718A1 (en) | 2016-06-24 | 2017-12-28 | Infinity Pharmaceuticals, Inc. | Combination therapies |
US20220064145A1 (en) * | 2020-08-28 | 2022-03-03 | Hanmi Science Co., Ltd. | Synthesis of poziotinib derivative |
Family Cites Families (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4335127A (en) * | 1979-01-08 | 1982-06-15 | Janssen Pharmaceutica, N.V. | Piperidinylalkyl quinazoline compounds, composition and method of use |
KR910006138B1 (ko) | 1986-09-30 | 1991-08-16 | 에자이 가부시끼가이샤 | 환상아민 유도체 |
US4921863A (en) * | 1988-02-17 | 1990-05-01 | Eisai Co., Ltd. | Cyclic amine derivatives |
US5721237A (en) | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
AU661533B2 (en) * | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
WO1996030347A1 (en) | 1995-03-30 | 1996-10-03 | Pfizer Inc. | Quinazoline derivatives |
GB9508535D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivative |
DE69613367T2 (de) | 1995-04-27 | 2002-04-18 | Astrazeneca Ab | Chinazolin derivate |
GB9508537D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US5747498A (en) * | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
GB9514265D0 (en) | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
SK285141B6 (sk) | 1996-02-13 | 2006-07-07 | Astrazeneca Uk Limited | Použitie chinazolínového derivátu, chinazolínový derivát, spôsob jeho prípravy a farmaceutická kompozícia, ktorá ho obsahuje |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
GB9603097D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline compounds |
EP0892789B2 (en) | 1996-04-12 | 2009-11-18 | Warner-Lambert Company LLC | Irreversible inhibitors of tyrosine kinases |
GB9607729D0 (en) | 1996-04-13 | 1996-06-19 | Zeneca Ltd | Quinazoline derivatives |
EP0912559B1 (en) | 1996-07-13 | 2002-11-06 | Glaxo Group Limited | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
WO2000009481A1 (fr) | 1998-08-11 | 2000-02-24 | Takeda Chemical Industries, Ltd. | Composes d'amide cyclique, procedes de production correspondants, intermediaires correspondants et herbicides |
ES2457396T3 (es) | 1998-09-29 | 2014-04-25 | Wyeth Holdings Llc | 3-Cianoquinolinas sustituidas como inhibidores de las proteínas tirosina quinasas |
US6297258B1 (en) * | 1998-09-29 | 2001-10-02 | American Cyanamid Company | Substituted 3-cyanoquinolines |
TW575567B (en) | 1998-10-23 | 2004-02-11 | Akzo Nobel Nv | Serine protease inhibitor |
UA71945C2 (en) | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
BR0008524A (pt) * | 1999-02-27 | 2001-12-18 | Boehringer Ingelheim Pharma | Heterociclos bicìclicos, composiçõesfarmacêuticas que contêm esses compostos, seuuso e processos para a sua prerapação |
DE19911509A1 (de) * | 1999-03-15 | 2000-09-21 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
US6258820B1 (en) | 1999-03-19 | 2001-07-10 | Parker Hughes Institute | Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines |
GB9917408D0 (en) | 1999-07-23 | 1999-09-22 | Smithkline Beecham Plc | Compounds |
GB9922171D0 (en) * | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Chemical compounds |
RU2002110461A (ru) | 1999-09-21 | 2004-03-10 | Астразенека Аб (Se) | Производные хиназолина и их применение в качестве фармацевтических веществ |
US7160889B2 (en) * | 2000-04-07 | 2007-01-09 | Astrazeneca Ab | Quinazoline compounds |
UA73993C2 (uk) * | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
DK1292591T3 (da) | 2000-06-22 | 2005-05-30 | Pfizer Prod Inc | Bicykliske derivater til behandling af abnorm cellevækst |
DE10040527A1 (de) | 2000-08-18 | 2002-02-28 | Boehringer Ingelheim Pharma | Chinazoline und Verfahren zu ihrer Herstellung |
US20020082270A1 (en) * | 2000-08-26 | 2002-06-27 | Frank Himmelsbach | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
DE60119939T2 (de) | 2000-09-21 | 2006-11-30 | Smithkline Beecham P.L.C., Brentford | Chinolinderivate als antibakterielle mittel |
US6849625B2 (en) | 2000-10-13 | 2005-02-01 | Astrazeneca Ab | Quinazoline derivatives with anti-tumour activity |
AU2002212436A1 (en) | 2000-10-25 | 2002-05-06 | Astrazeneca Ab | Quinazoline derivatives |
AU2002210714A1 (en) | 2000-11-02 | 2002-06-11 | Astrazeneca Ab | Substituted quinolines as antitumor agents |
DE60130017T2 (de) | 2000-11-22 | 2008-05-15 | Novartis Ag | Kombination enthaltend ein mittel zur verminderung von vegf-aktivität und ein mittel zur verminderung von egf-aktivität |
AUPR201600A0 (en) | 2000-12-11 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivative |
GB0101577D0 (en) | 2001-01-22 | 2001-03-07 | Smithkline Beecham Plc | Compounds |
WO2002062767A1 (fr) | 2001-02-07 | 2002-08-15 | Sumitomo Pharmaceuticals Company, Limited | Nouveaux derives de quinazoline |
NZ516873A (en) | 2001-02-12 | 2003-11-28 | Warner Lambert Co | Compositions containing retinoids and erb inhibitors and their use in inhibiting retinoid skin damage |
WO2002066445A1 (fr) | 2001-02-21 | 2002-08-29 | Mitsubishi Pharma Corporation | Derives de la quinazoline |
US6562319B2 (en) * | 2001-03-12 | 2003-05-13 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy |
WO2002094790A1 (fr) * | 2001-05-23 | 2002-11-28 | Mitsubishi Pharma Corporation | Compose heterocyclique condense et son utilisation medicale |
EP1429765A2 (en) * | 2001-09-14 | 2004-06-23 | Methylgene, Inc. | Inhibitors of histone deacetylase |
CN100343238C (zh) * | 2001-11-03 | 2007-10-17 | 阿斯特拉曾尼卡有限公司 | 用作抗肿瘤药物的喹唑啉衍生物 |
GB0126433D0 (en) * | 2001-11-03 | 2002-01-02 | Astrazeneca Ab | Compounds |
TW200813014A (en) * | 2002-03-28 | 2008-03-16 | Astrazeneca Ab | Quinazoline derivatives |
KR101064530B1 (ko) * | 2002-03-30 | 2011-09-14 | 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 | 티로신 키나아제 억제제로서의 4-(n-페닐아미노)-퀴나졸린/퀴놀린, 이를 함유하는 약제학적 조성물 및 이의 제조방법 |
US6924285B2 (en) * | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
CA2491191C (en) * | 2002-07-15 | 2014-02-04 | Exelixis, Inc. | Receptor-type kinase modulators and methods of use |
GB0309009D0 (en) | 2003-04-22 | 2003-05-28 | Astrazeneca Ab | Quinazoline derivatives |
GB0309850D0 (en) * | 2003-04-30 | 2003-06-04 | Astrazeneca Ab | Quinazoline derivatives |
GB0317665D0 (en) * | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Qinazoline derivatives |
JP2007500177A (ja) * | 2003-07-29 | 2007-01-11 | アストラゼネカ アクチボラグ | チロシンキナーゼ阻害剤としてのピペリジルキナゾリン誘導体 |
GB0321648D0 (en) * | 2003-09-16 | 2003-10-15 | Astrazeneca Ab | Quinazoline derivatives |
US20080234263A1 (en) * | 2003-09-16 | 2008-09-25 | Laurent Francois Andre Hennequin | Quinazoline Derivatives |
CA2539022A1 (en) * | 2003-09-16 | 2005-03-24 | Astrazeneca Ab | Quinazoline derivatives as tyrosine kinase inhibitors |
WO2005026157A1 (en) * | 2003-09-16 | 2005-03-24 | Astrazeneca Ab | Quinazoline derivatives |
JP4795952B2 (ja) * | 2003-09-16 | 2011-10-19 | アストラゼネカ アクチボラグ | チロシンキナーゼ阻害剤としてのキナゾリン誘導体 |
US20070037837A1 (en) * | 2003-09-19 | 2007-02-15 | Hennequin Laurent Francois A | Quinazoline derivatives |
DE602004004553T2 (de) * | 2003-09-19 | 2007-10-25 | Astrazeneca Ab | Chinazolinderivate |
AU2004276055A1 (en) * | 2003-09-25 | 2005-04-07 | Astrazeneca Ab | Quinazoline derivatives |
GB0326459D0 (en) * | 2003-11-13 | 2003-12-17 | Astrazeneca Ab | Quinazoline derivatives |
US7632840B2 (en) * | 2004-02-03 | 2009-12-15 | Astrazeneca Ab | Quinazoline compounds for the treatment of hyperproliferative disorders |
WO2005118572A1 (en) * | 2004-06-04 | 2005-12-15 | Astrazeneca Ab | Quinazoline derivatives as erbb receptor tyrosine kinases |
DE602005026865D1 (de) * | 2004-12-14 | 2011-04-21 | Astrazeneca Ab | Pyrazolopyrimidinverbindungen als antitumormittel |
GB0504474D0 (en) * | 2005-03-04 | 2005-04-13 | Astrazeneca Ab | Chemical compounds |
GB0504475D0 (en) * | 2005-03-04 | 2005-04-13 | Astrazeneca Ab | Chemical compounds |
GB0508717D0 (en) * | 2005-04-29 | 2005-06-08 | Astrazeneca Ab | Chemical compounds |
GB0508715D0 (en) * | 2005-04-29 | 2005-06-08 | Astrazeneca Ab | Chemical compounds |
US7820683B2 (en) * | 2005-09-20 | 2010-10-26 | Astrazeneca Ab | 4-(1H-indazol-5-yl-amino)-quinazoline compounds as erbB receptor tyrosine kinase inhibitors for the treatment of cancer |
EP1940825A1 (en) * | 2005-09-20 | 2008-07-09 | Astra Zeneca AB | Quinazoline derivatives as anticancer agents |
EP1960371B1 (en) * | 2005-12-02 | 2009-09-16 | AstraZeneca AB | Quinazoleine derivatives used as inhibitors of erbb tyrosine kinase |
WO2007070509A2 (en) * | 2005-12-13 | 2007-06-21 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Epithelial sodium channel inhibiting agents and uses therefor |
-
2003
- 2003-09-25 GB GBGB0322409.4A patent/GB0322409D0/en not_active Ceased
-
2004
- 2004-09-22 KR KR1020067007934A patent/KR20060095767A/ko not_active Application Discontinuation
- 2004-09-22 US US10/572,794 patent/US7838530B2/en not_active Expired - Fee Related
- 2004-09-22 CN CN200480034739A patent/CN100577658C/zh not_active Expired - Fee Related
- 2004-09-22 CN CNB2004800345317A patent/CN100558725C/zh not_active Expired - Fee Related
- 2004-09-22 EP EP04768680A patent/EP1668006A1/en not_active Withdrawn
- 2004-09-22 CA CA002540019A patent/CA2540019A1/en not_active Abandoned
- 2004-09-22 JP JP2006527495A patent/JP2007506725A/ja active Pending
- 2004-09-22 AU AU2004276067A patent/AU2004276067A1/en not_active Abandoned
- 2004-09-22 BR BRPI0414772-3A patent/BRPI0414772A/pt not_active Application Discontinuation
- 2004-09-22 MX MXPA06003422A patent/MXPA06003422A/es unknown
- 2004-09-22 WO PCT/GB2004/004137 patent/WO2005030765A1/en active Application Filing
-
2006
- 2006-03-23 IL IL174533A patent/IL174533A0/en unknown
- 2006-03-24 ZA ZA200602434A patent/ZA200602434B/en unknown
- 2006-03-24 ZA ZA200602444A patent/ZA200602444B/en unknown
- 2006-04-20 NO NO20061746A patent/NO20061746L/no not_active Application Discontinuation
-
2010
- 2010-10-12 US US12/902,543 patent/US20110237610A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2005030765A1 (en) | 2005-04-07 |
CN1886399A (zh) | 2006-12-27 |
CN100558725C (zh) | 2009-11-11 |
JP2007506725A (ja) | 2007-03-22 |
CA2540019A1 (en) | 2005-04-07 |
US20110237610A1 (en) | 2011-09-29 |
US20060287295A1 (en) | 2006-12-21 |
US7838530B2 (en) | 2010-11-23 |
CN1882580A (zh) | 2006-12-20 |
EP1668006A1 (en) | 2006-06-14 |
AU2004276067A1 (en) | 2005-04-07 |
ZA200602434B (en) | 2007-07-25 |
CN100577658C (zh) | 2010-01-06 |
ZA200602444B (en) | 2007-09-26 |
GB0322409D0 (en) | 2003-10-29 |
IL174533A0 (en) | 2006-08-01 |
KR20060095767A (ko) | 2006-09-01 |
MXPA06003422A (es) | 2006-06-20 |
NO20061746L (no) | 2006-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0414772A (pt) | derivado de quinazolina, composto, processo para a preparação de um derivado de quinazolina, composição farmacêutica, uso de um derivado de quinazolina, e, método para produzir um efeito anti-proliferativo em um animal de sangue quente | |
BR0308670A (pt) | Derivado de quinazolina ou um sal deste farmaceuticamente aceitável, processo para a preparação do mesmo, composição farmacêutica, uso do dito derivado ou de seu sal, método para produzir um efeito anti-proliferativo em um animal de sangue quente em necessidade de tal tratamento, e, composto ou um sal deste. | |
BRPI0414532A (pt) | composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, método para produzir um efeito anti-proliferativo em um animal de sangue quente | |
BRPI0414735A (pt) | derivado de quinazolina, composto, composição farmacêutica, uso de derivado de quinazolina, método para produzir um efeito anti-proliferativo em um animal de sangue quente, e, processo para a preparação de um derivado de quinazolina | |
BRPI0511741A (pt) | derivado de quinazolina ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, processo para a preparação de um derivado de quinazolina ou de um sal farmaceuticamente aceitável do mesmo | |
BR0213842A (pt) | Derivado de quinazolina ou um sal deste farmaceuticamente aceitável, processo para a preparação do mesmo, composição farmacêutica, e, uso do derivado de quinazolina ou de um sal deste farmaceuticamente aceitável | |
BR0213843A (pt) | Derivado de quinazolina, processo para a preparação de um derivado de quinazolina, composição farmacêutica, e, uso de um derivado de quinazolina | |
BRPI0414489A8 (pt) | derivado de quinazolina, composição farmacêutica, uso de um derivado de quinazolina, e, processo para a preparação de um derivado de quinazolina | |
BR0113358A (pt) | Derivado de quinazolina ou de um seu sal farmaceuticamente aceitável, processo para a sua preparação, composição farmacêutica, e, uso do derivado ou de um seu sal farmaceuticamente aceitável | |
BR0215312A (pt) | Uso de um composto, método para inibir a aurora quinase em um animal de sangue quente, composto, composição farmacêutica, e, processo para a preparação de um composto | |
BRPI0413066A (pt) | derivado de quinazolina, ou um sal farmaceuticamente aceitável, ou um éster farmaceuticamente aceitável do mesmo, da fórmula i, uso e processo para a preparação do mesmo, composto, composição farmacêutica, e, métodos para a produção de um efeito antiproliferativo em um animal de sangue quente, para a prevenção ou tratamento de um tumor, para prover um efeito inibitório de tirosina quinase de egfr seletivo, e para tratar um cáncer em um animal de sangue quente | |
BRPI0516093A (pt) | derivado de quinazolina, processo para a preparação do mesmo, composição farmacêutica, uso de um derivado de quinazolina, e, método para tratamento de distúrbios proliferativos celulares em um animal de sanque quente | |
BRPI0414488A (pt) | derivado de quinazolina, composição farmacêutica, uso de um derivado de quinazolina, métodos para produzir um efeito anti - proliferativo em um animal de sangue quente, para prevenção ou tratamento de tumores em um aminal de sangue quente, para fornecer um efeito inibidor da tirosina quinase de egfr seletivo em um animal de sangue quente e para tratar um cáncer em um animal de sangue quente e, processo para a preparação de um derivado de quinazolina | |
BRPI0408681A (pt) | compostos, composições farmacêuticas, uso de um derivado da 1,2,3,4-tetraidroisoquinolina, método para tratar ou prevenir doenças, processo para a manufatura de composições farmacêuticas, e, uso de um ou mais compostos | |
BR0307351A (pt) | Composto, composição farmacêutica, método para tratar uma condição ou estado de doença mediados pela atividade de p38 quinase ou mediados por citocinas produzidas pela atividade de p38 quinase, uso de um composto, e, processo para preparar um composto | |
BR0309167A (pt) | Composto, processo para a produção de um composto, composição farmacêutica, uso do composto, método para o tratamento de um sujeito afetado por uma condição patológica ou doença e produto de combinação | |
BRPI0513058A (pt) | derivado de pirimidina ou um sal, solvato ou pró-droga farmaceuticamente aceitável do mesmo, processo para a preparação do mesmo, composição farmacêutica, uso de um derivado de pirimidina ou de um sal, solvato ou pró-droga farmaceuticamente aceitável do mesmo, e, método para produzir um efeito anti-proliferativo em um animal de sangue quente | |
BR0312464A (pt) | Inibidores de tirosina quinases | |
BRPI0416605A (pt) | composto, processo para preparar um composto, uso de um composto, métodos de inibição da atividade de trk, de tratamento ou profilaxia de cáncer, e de produção de um efeito anti-proliferativo em um animal de sangue quente e composição farmacêutica | |
BR9911482A (pt) | Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto | |
BRPI0407834A (pt) | composto, processo para a manufatura do mesmo, composição, processo para a manufatura da mesma, método de tratamento ou prevenção de um distúrbio mediado por proteìna quinase em um indivìduo, uso de um composto, ensaio para determinar a atividade dos compostos, e, método de inibição da atividade ou função de uma proteìna quinase | |
BRPI0410563A (pt) | derivados de pirazol-quinazolina processo para sua preparação e seu uso como inibidores de quinase | |
BRPI0607927A2 (pt) | derivados de pirazol-pirimidina | |
BRPI0007487B8 (pt) | difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase | |
BRPI0411255A (pt) | composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |